AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged instruction (gold stage)
Number of subjects: 495
Study 11719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged instruction (bronze stage)
Number of subjects: 495
Study 11719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged instruction (silver stage: 50 compressions to 5 breaths)
Number of subjects: 495
Study 9223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid neostigmine 100 micrograms
Number of subjects: 100
Study 9223199 — intervention group
Group type: COMPARATOR
Intervention: Saline (S group)
Number of subjects: 100
Study 9223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (N group)
Number of subjects: 100
Study 9223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (P group)
Number of subjects: 100
Study 9223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (M group)
Number of subjects: 100
Study 9223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (D group)
Number of subjects: 100
Study 8355037 — intervention group
Group type: COMPARATOR
Intervention: 1 year of adjuvant CMFVP chemotherapy
Number of subjects: 445
Study 8355037 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of adjuvant CMFVP chemotherapy
Number of subjects: 445
Study 3302806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 60
Study 3302806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 60
Study 30479561 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Watson's Theory of Human Caring
Number of subjects: 135
Study 30479561 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 135
Study 26701364 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sublingual nitroglycerin
Number of subjects: 80
Study 26701364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25711955 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein (HP) breakfast (32 g protein)
Number of subjects: 35
Study 25711955 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-protein (NP) breakfast (12 g protein)
Number of subjects: 35
Study 23107605 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 53
Study 23107605 — intervention group
Group type: COMPARATOR
Intervention: No EPO
Number of subjects: 53
Study 23107605 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study 21181687 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-hour presentation on the evaluation of ECGs for STEMI (Group 2)
Number of subjects: 33
Study 21181687 — intervention group
Group type: COMPARATOR
Intervention: Handout describing the evaluation of ECGs for STEMI (Group 1)
Number of subjects: 33
Study 21181687 — intervention group
Group type: EXPERIMENTAL
Intervention: All students (initial pre-test vs five-month retest)
Number of subjects: 33
Study 18447219 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-separated moxibustion at Shenque (CV 8)
Number of subjects: 136
Study 18447219 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Smecta (Control)
Number of subjects: 136
Study 17388006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 100
Study 17388006 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin
Number of subjects: 100
Study 17388006 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 100
Study 12962953 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cerclage
Number of subjects: 2175
Study 12962953 — intervention group
Group type: COMPARATOR
Intervention: Cervical cerclage
Number of subjects: 2175
Study 10774248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 2 micrograms/kg/day
Number of subjects: 18
Study 10774248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg/day
Number of subjects: 18
Study 10774248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 10 micrograms/kg/day
Number of subjects: 18
Study 8897357 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (PCN) administered at a dose of 1,200,000 u, intramuscularly at 3-week intervals for at least one year.
Number of subjects: 45
Study 8897357 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (PCN)
Number of subjects: 45
Study 1677774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem (225 mg)
Number of subjects: 30
Study 1677774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4.5 mg)
Number of subjects: 30
Study 1677774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6647190 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg)
Number of subjects: 96
Study 6647190 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 g)
Number of subjects: 96
Study 12206065 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Exchange Condition (access to NS via an experimental needle exchange program)
Number of subjects: 176
Study 12206065 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy Sales Condition (access to NS via legal sales of nonprescription NS)
Number of subjects: 176
Study 12206065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Needle Exchange and Pharmacy Sales)
Number of subjects: 176
Study 30413154 — intervention group
Group type: EXPERIMENTAL
Intervention: Precizon toric IOL
Number of subjects: 40
Study 30413154 — intervention group
Group type: COMPARATOR
Intervention: Tecnis toric IOL
Number of subjects: 40
Study 27676664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dose radiofrequency followed by continuous thermal radiofrequency ablation
Number of subjects: 0
Study 27676664 — intervention group
Group type: COMPARATOR
Intervention: Thermal radiofrequency ablation alone
Number of subjects: 0
Study 24886232 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 1681
Study 24886232 — intervention group
Group type: COMPARATOR
Intervention: Life-prolonging/curative treatment
Number of subjects: 1681
Study 22245134 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier container
Number of subjects: 0
Study 22245134 — intervention group
Group type: COMPARATOR
Intervention: Lighter container
Number of subjects: 0
Study 20715523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsation group
Number of subjects: 100
Study 20715523 — intervention group
Group type: COMPARATOR
Intervention: US group
Number of subjects: 100
Study 18554712 — intervention group
Group type: EXPERIMENTAL
Intervention: LT-patch (37.5 mug of heat-labile toxin from E. coli)
Number of subjects: 201
Study 18554712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 15922193 — intervention group
Group type: EXPERIMENTAL
Intervention: AI/AN race
Number of subjects: 2215
Study 15922193 — intervention group
Group type: COMPARATOR
Intervention: Caucasian race
Number of subjects: 2215
Study 12390335 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg melatonin
Number of subjects: 24
Study 12390335 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg melatonin
Number of subjects: 24
Study 12390335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10439603 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based small-group learning (PBSGL) intervention via the Internet for 11 family physicians over two months with facilitator and geriatric psychiatrists.
Number of subjects: 23
Study 10439603 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving similar educational resources via the Internet without small-group interaction for 12 family physicians.
Number of subjects: 23
Study 7794984 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist orthoses
Number of subjects: 69
Study 7794984 — intervention group
Group type: COMPARATOR
Intervention: No wrist orthoses
Number of subjects: 69
Study 2146370 — intervention group
Group type: EXPERIMENTAL
Intervention: resection and continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUdR) in arm A2
Number of subjects: 91
Study 2146370 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAI only in arm B2
Number of subjects: 91
Study 2146370 — intervention group
Group type: EXPERIMENTAL
Intervention: systemic fluorouracil followed by CHAI in arm C2
Number of subjects: 91
Study 2146370 — intervention group
Group type: COMPARATOR
Intervention: resection only in arm A1
Number of subjects: 91
Study 1032070 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.15 mg and 0.3 mg)
Number of subjects: 0
Study 1032070 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.6 mg and 1.2 mg)
Number of subjects: 0
Study 1032070 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg and 10 mg)
Number of subjects: 0
Study 31053885 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS posterior approach
Number of subjects: 64
Study 31053885 — intervention group
Group type: COMPARATOR
Intervention: mDL approach
Number of subjects: 64
Study 26418205 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sevoflurane during CPB
Number of subjects: 103
Study 26418205 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen-air mixture)
Number of subjects: 103
Study 24722496 — intervention group
Group type: EXPERIMENTAL
Intervention: INT131 0.5 mg
Number of subjects: 367
Study 24722496 — intervention group
Group type: EXPERIMENTAL
Intervention: INT131 1 mg
Number of subjects: 367
Study 24722496 — intervention group
Group type: EXPERIMENTAL
Intervention: INT131 2 mg
Number of subjects: 367
Study 24722496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 367
Study 24722496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 23755953 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine semen analyses, sperm DNA, and chromatin assessments
Number of subjects: 129
Study 20838058 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (CAP)
Number of subjects: 71
Study 20838058 — intervention group
Group type: COMPARATOR
Intervention: CEF (cyclophosphamide/epirubicin/5-fluorouracil)
Number of subjects: 71
Study 18982032 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1 drop immediately after surgery
Number of subjects: 60
Study 18982032 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1 drop every 12 hours starting immediately after surgery
Number of subjects: 60
Study 18982032 — intervention group
Group type: COMPARATOR
Intervention: No ocular hypotensive medication (control group)
Number of subjects: 60
Study 15974850 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing and polishing
Number of subjects: 24
Study 15974850 — intervention group
Group type: COMPARATOR
Intervention: Polishing alone
Number of subjects: 24
Study 12832740 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 100
Study 12832740 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 10804484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (30 minutes of exercise at RPE level 13, three times a week for 10 weeks)
Number of subjects: 16
Study 10804484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 10804484 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pre-post change in DBP between groups
Number of subjects: 16
Study 10804484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 16
Study 1779870 — intervention group
Group type: EXPERIMENTAL
Intervention: Late umbilical cord clamping
Number of subjects: 554
Study 1779870 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping
Number of subjects: 554
Study 6320580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin-pivmecillinam (PAPM)
Number of subjects: 82
Study 6320580 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulphamethoxazole (TMPS)
Number of subjects: 82
Study 28936692 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic relationship in music therapy
Number of subjects: 48
Study 29575669 — intervention group
Group type: EXPERIMENTAL
Intervention: prepCheck-supported self-assessment (n=24)
Number of subjects: 47
Study 29575669 — intervention group
Group type: COMPARATOR
Intervention: Conventional faculty supervision (n=23)
Number of subjects: 47
Study 26525206 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer suture anastomosis (SLA)
Number of subjects: 252
Study 26525206 — intervention group
Group type: COMPARATOR
Intervention: Double-layer suture anastomosis (DLA)
Number of subjects: 252
Study 26298934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense bladder control education
Number of subjects: 0
Study 26298934 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 22306844 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate and ibuprofen (combined therapy)
Number of subjects: 71
Study 22306844 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 71
Study 20839311 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal
Number of subjects: 124
Study 20839311 — intervention group
Group type: COMPARATOR
Intervention: Credible active comparison condition
Number of subjects: 124
Study 17599766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg daily)
Number of subjects: 98
Study 17599766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 17599766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (observational study)
Number of subjects: 98
Study 17599766 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (observational study)
Number of subjects: 98
Study 16053839 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire fixation
Number of subjects: 3
Study 16053839 — intervention group
Group type: COMPARATOR
Intervention: Rigid internal fixation (RIF)
Number of subjects: 3
Study 12475666 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 190
Study 9536505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg/day, increasing to 10 mg/day after 2 weeks
Number of subjects: 32
Study 9536505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 10 mg/day
Number of subjects: 32
Study 9536505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 mg/day and 10 mg/day
Number of subjects: 32
Study 9536505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7628027 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (30 micrograms.kg‐1)
Number of subjects: 156
Study 7628027 — intervention group
Group type: COMPARATOR
Intervention: Morphine (150 micrograms.kg‐1)
Number of subjects: 156
Study 2021198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 39
Study 6124440 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (250 micrograms)
Number of subjects: 10
Study 6124440 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (25 micrograms)
Number of subjects: 10
Study 6124440 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (100 micrograms)
Number of subjects: 10
Study 6124440 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (10 micrograms)
Number of subjects: 10
Study 6124440 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (25 micrograms)
Number of subjects: 10
Study 6124440 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (2.5 micrograms)
Number of subjects: 10
Study 31694810 — intervention group
Group type: EXPERIMENTAL
Intervention: Authors' full International Committee of Medical Journal Editors format conflict of interest disclosures
Number of subjects: 838
Study 31694810 — intervention group
Group type: COMPARATOR
Intervention: No authors' conflict of interest disclosures
Number of subjects: 838
Study 31694810 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterfactual scores
Number of subjects: 838
Study 28353611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lumbar facet joint pulsed radiofrequency (PRF)
Number of subjects: 60
Study 28353611 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular lumbar facet joint corticosteroid injection (ICI)
Number of subjects: 60
Study 29797981 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy
Number of subjects: 82
Study 29797981 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid combined with dehydrant therapy
Number of subjects: 82
Study 25268438 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 282
Study 25268438 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 282
Study 25268438 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 282
Study 25268438 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 282
Study 22424787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24IU)
Number of subjects: 0
Study 22424787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 22424787 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24IU) administered in the second session
Number of subjects: 0
Study 22424787 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unknown to participants and experimenter)
Number of subjects: 0
Study 19367322 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 300
Study 19367322 — intervention group
Group type: COMPARATOR
Intervention: Screening (Control)
Number of subjects: 300
Study 17617812 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungi on walls of the house
Number of subjects: 1760
Study 17617812 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent use of microwave oven at home
Number of subjects: 1760
Study 15042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 847
Study 15042116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 847
Study 11782325 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of racemic methadone (initial doses of 3 to 6 mg followed by 6 to 12 mg over 24 hr)
Number of subjects: 90
Study 11782325 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of racemic methadone (repeated boluses of 3 to 6 mg every eight hours)
Number of subjects: 90
Study 9633672 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g TFD (tryptophan-free amino acid drink)
Number of subjects: 10
Study 9633672 — intervention group
Group type: COMPARATOR
Intervention: 25-g TFD (control drink)
Number of subjects: 10
Study 7866680 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin hypoglycaemia (IH) test
Number of subjects: 16
Study 7866680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 16
Study 1967919 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg OD
Number of subjects: 0
Study 1967919 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg BID
Number of subjects: 0
Study 1967919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide 200 micrograms/day
Number of subjects: 56
Study 7350203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7350203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide
Number of subjects: 56
Study 31776620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 305
Study 31776620 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 305
Study 31870427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonplacement of a cervical drainage tube
Number of subjects: 110
Study 31870427 — intervention group
Group type: COMPARATOR
Intervention: Placement of a cervical drainage tube
Number of subjects: 110
Study 27937096 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib
Number of subjects: 499
Study 27937096 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus erlotinib
Number of subjects: 499
Study 26664397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 100 mg/day
Number of subjects: 90
Study 26664397 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 90
Study 26664397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 23680127 — intervention group
Group type: EXPERIMENTAL
Intervention: ABThera Open Abdomen Negative Pressure Therapy System
Number of subjects: 0
Study 23680127 — intervention group
Group type: COMPARATOR
Intervention: Barker's vacuum pack
Number of subjects: 0
Study 21827934 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality teaching program (8-week intervention using audio CDs for home-based use)
Number of subjects: 15
Study 17597132 — intervention group
Group type: EXPERIMENTAL
Intervention: Vipassana meditation course
Number of subjects: 0
Study 17597132 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 15619332 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide studies of upper GI function
Number of subjects: 32
Study 15619332 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire on upper GI symptoms
Number of subjects: 32
Study 15619332 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal clearance studies
Number of subjects: 32
Study 11479469 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD mode with the rate‐smoothing algorithm (RSA) on
Number of subjects: 14
Study 11479469 — intervention group
Group type: COMPARATOR
Intervention: OOO mode
Number of subjects: 14
Study 11479469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-smoothing mode
Number of subjects: 14
Study 11479469 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA ON arm
Number of subjects: 14
Study 9493805 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 3 mg/kg
Number of subjects: 0
Study 9493805 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 10 mg/kg
Number of subjects: 0